Societe Generale’s Novavax NVAX Stock Holding History

Societe Generale’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	$98K	Buy	+675	New	+$77.4K	﹤0.01%	2395

Other funds holding NVAX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Societe Generale's NVAX Position: Q2 2016 in Review

Societe Generale opened a new position in Novavax (NVAX) in Q2 2016: 675 shares worth $98K. The stake represents ﹤0.01% of the portfolio and ranks #2395 among its holdings.

186 funds tracked by Wall St. Rank hold NVAX as of Q2 2016.

Societe Generale held 675 shares of Novavax worth $98K as of Q2 2016.
Novavax was a new Societe Generale position in Q2 2016.
Novavax made up ﹤0.01% of Societe Generale's portfolio in Q2 2016, its #2395 holding.
186 funds tracked by Wall St. Rank held Novavax as of Q2 2016.

Based on Societe Generale's 13F filing for Q2 2016, filed 2 Aug 2016.